Last week, the Food and Drug Administration (FDA) listened to presentations and comments from several members of an expert FDA advisory committee regarding the benefit-to-risk ratio of Long Acting Beta-agonist drugs (LABAs) -- namely Serevent (salmeterol) , Foradil (formoterol) , Advair (a combination of fluticasone and salmeterol) and Symbicort (a combination of budesonide and formoterol).
The FDA advisory panel voted, unanimously, that the benefit of Advair and Symbicort outweighed the risks of adverse effects in adults , but that the risks of Serevent and Foradil -- particularly when used without a anti-inflammatory steroid -- outweighed the benefits for asthmatics.
So, what does all of this mean for you?
Continue reading "Advair and Symbicort: "Benefits Outweight the Risk" Says an FDA Advisory Comittee.
Get more information on Advair, Symbicort and Long-Acting Beta Agonists here.
While it has not yet been approved in the United States, Symbicort may some day be available as a rescue inhaler as well as a preventative medicine. In this sense, it may be the dream inhaler we asthmatics have been yearning for.
In Europe, Australia, and recently Canada , Symbicort has been approved for this purpose. The program is called the SMART program , and you can read about it by clicking here .
According to asthmansw.org , SMART is an acronym for "Symbicort Maintenance And Reliever Therapy." The SMART program is explained here:
"It is a daily asthma management approach that allows you to use a single Symbicort inhaler as both a preventer and a reliever. Currently Symbicort is the only medication available for use as BOTH a maintenance preventer and reliever. SMART works this way as it contains two different types of medicine in the same inhaler - a preventer (Pulmicort [Budesonide]) as the long-acting reliever which helps to c...
While the economy sputters, the long acting bronchodilator/ corticosteroid combination inhaler market is booming. While big pharmaceutical companies fight it out to maintain or gain a piece of this pie, we asthmatics should be the beneficiaries.
New drugs, and new marketing ploys, may soon be available in the U.S. market to compete with Advair and Symbicort, which will provide more options for asthmatics like you and me. Plus, as we all know, more competition means lower costs.
Advair and Symbicort are asthma combination inhalers that have both a long acting bronchodilator (LAB) to treat the airway narrowing (bronchospasm) component of asthma, but also a corticosteroid to treat the chronic inflammation side of asthma.
Advair (called Seritide in Europe), which is marketed by GlaxoSmithKline (GSK) out of London, became available in the U.S. in 2001, and presently has the lead in this booming market. Adviar consists of the LAB Salmeterol (Serev...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.